Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 32 of 55 for:    stem cell arthritis AND stem cell transplantation

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01919619
Recruitment Status : Recruiting
First Posted : August 9, 2013
Last Update Posted : August 20, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This pilot clinical trial studies the side effects of lenalidomide and ipilimumab after stem cell transplant in treating patients with hematologic or lymphoid malignancies. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide with ipilimumab may be a better treatment for hematologic or lymphoid malignancies.

Condition or disease Intervention/treatment Phase
B-Cell Non-Hodgkin Lymphoma Hematopoietic and Lymphoid Cell Neoplasm Leukemia Lymphoma Plasma Cell Myeloma T-Cell Non-Hodgkin Lymphoma Biological: Ipilimumab Drug: Lenalidomide Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the safety of lenalidomide in combination with ipilimumab in autologous and allogeneic stem cell transplantation.

SECONDARY OBJECTIVES:

I. Overall response rate. II. Overall survival, progression-free survival. III. Cumulative incidence of acute and chronic graft-versus-host disease (GVHD) with the competing risk of relapse in allogeneic transplant patients.

OUTLINE:

Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab intravenously (IV) over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 3, 6, 12, 24, and 36 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Actual Study Start Date : November 4, 2013
Estimated Primary Completion Date : November 30, 2019
Estimated Study Completion Date : November 30, 2019


Arm Intervention/treatment
Experimental: Treatment (lenalidomide and ipilimumab)
Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Biological: Ipilimumab
Given IV
Other Names:
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • CC5013
  • CDC 501
  • Revlimid




Primary Outcome Measures :
  1. Toxicity rate [ Time Frame: Up to 30 days following the last dose of study drugs ]
    Graded according to the National Cancer Institute Common Toxicity Criteria. The toxicity rate will be estimated in each arm along with a corresponding 95% credible interval. Toxicity will also be summarized by arm, type, and grade.


Secondary Outcome Measures :
  1. Response rate [ Time Frame: 112 days ]
    The response rate at the end of four cycles will be estimated with a 95% confidence interval.

  2. Overall response rate [ Time Frame: Up to 36 months ]
    The overall response rate will be estimated with a 95% confidence interval.

  3. Overall survival [ Time Frame: Up to 36 months ]
    Kaplan-Meier survival curves will be used to estimate overall survival. Cox proportional hazards regression analysis will be used to model the association between overall survival and disease and demographic covariates of interest, including data from the correlative cytokine, immune, and pharmacokinetic studies.

  4. Progression-free survival [ Time Frame: Up to 36 months ]
    Kaplan-Meier survival curves will be used to estimate progression-free survival. Cox proportional hazards regression analysis will be used to model the association between overall survival and disease and demographic covariates of interest, including data from the correlative cytokine, immune, and pharmacokinetic studies.

  5. Cumulative incidence of acute graft-versus-host disease [ Time Frame: Up to 30 days following the last dose of study drugs ]
    The method of Gooley et al will be used to estimate the cumulative incidence of acute graft-versus-host disease with the competing risk of relapse in allogeneic transplant patients.

  6. Cumulative incidence of chronic graft-versus-host disease [ Time Frame: Up to 36 months ]
    The method of Gooley et al will be used to estimate the cumulative incidence of chronic graft-versus-host disease with the competing risk of relapse in allogeneic transplant patients.

  7. Incidence of other organ toxicity [ Time Frame: Up to 36 months ]
    Graded according to the National Cancer Institute Common Toxicity Criteria.

  8. Incidence of secondary immune-based disease [ Time Frame: Up to 36 months ]
    Secondary immune-based diseases include arthritis, lupus, and thyroid dysfunction.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hematologic or lymphoid malignancy
  • Autologous patients can be included anytime within 6 months post-transplant, if they had no signs of progression and meet one of the following criteria: i. leukemia; ii. lymphoma (all types of B and T cell lymphoma); iii. multiple myeloma
  • Allogeneic patients if: i. patients had engrafted donor cells (i.e., > 20% donor T-cell from peripheral blood [PB]/polymerase chain reaction [PCR]); and, ii. patients NOT in complete remission (CR) after their allogeneic transplant, and off tacrolimus and/or mycophenolate mofetil for at least 3 to 4 weeks with no signs of GVHD; or, iii. patients had evidence of relapse after their transplant who are off tacrolimus and/or mycophenolate mofetil or other immunosuppressants for GVHD for 3 to 4 weeks with no signs of GVHD (prednisone doses =< 10 mg are permitted as stated previously)
  • No active infection
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelets > 75 x 10^9/L
  • Able to adhere to the study visit schedule and other protocol requirements
  • Performance status: Eastern Cooperative Oncology Group (ECOG) 2 or less or Karnofsky of at least 60
  • Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-ECHO) within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
  • Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
  • Serum creatinine =< 1.6 mg/dL and creatinine clearance >= 30 ml/min; creatinine clearance will be calculated using the Cockcroft-Gault equation
  • Serum glutamate pyruvate transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT) less than 2 x the upper limit of normal range (unless related to Gilbert's disease or medications)
  • Direct bilirubin < 1.6 (unless related to Gilbert's disease or medications)
  • Patient or legally authorized representative able to sign informed consent
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to study entry

Exclusion Criteria:

  • Immunotherapy or chemotherapy with approved or investigational anticancer therapeutics within 4 weeks of first dose
  • Patients on alemtuzumab within 6 weeks prior to consenting
  • Active congestive heart failure (New York Heart Association [NYHA] class III to IV), symptomatic ischemia or conduction abnormalities uncontrolled by conventional interventions; myocardial infarction within 6 months of study entry
  • Deep vein thrombosis or pulmonary embolism within 3 months of study entry
  • Pregnant or breast-feeding females; (lactating females must agree not to breast-feed while taking lenalidomide)
  • Acute active infection requiring intravenous antibiotics, antiviral (except antiviral directed at hepatitis B), or antifungal agents within 14 days of first dose
  • Known human immunodeficiency virus (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [Sag] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)
  • Patients with other known malignancies within the past three years except: i. adequately treated basal or squamous cell skin cancer; ii. carcinoma in situ of the cervix; iii. prostate cancer with Gleason score < 6 with stable prostate-specific antigen (PSA) over the past three months; iv. breast cancer in situ with full surgical resection
  • Significant neuropathy (grades 3 to 4 or grade 2 pain)
  • Known hypersensitivity to thalidomide, lenalidomide or ipilimumab
  • Active life-threatening autoimmune disease
  • Active GVHD or recent GVHD and still on > 10 mg prednisone (or equivalent)
  • Prior auto-immune disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01919619


Contacts
Layout table for location contacts
Contact: Issa Khouri 713-792-8750 ikhouri@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Issa Khouri    713-792-8750      
Principal Investigator: Issa Khouri         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Issa Khouri M.D. Anderson Cancer Center

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01919619     History of Changes
Other Study ID Numbers: 2012-0947
NCI-2013-02213 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2012.0947
2012-0947 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: August 9, 2013    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, T-Cell
Lymphoma, B-Cell
Neoplasms, Plasma Cell
Lymphoma
Lymphoma, Non-Hodgkin
Multiple Myeloma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lenalidomide
Ipilimumab
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Antineoplastic Agents, Immunological